The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations.

Rachel GoldsteinNatalie RabkinNoa BuchmanAviya R JacobsKhaled SandoukaBruria RaccahTamar Fisher NegevIlan MatokMeir BialerMordechai Muszkat

Published in: CNS drugs (2024)

. Therefore, prospective controlled studies are required to examine the possible non-pharmacokinetic mechanism of the effect of the LEV-apixaban or LEV-rivaroxaban combination on patients' outcomes.

Keyphrases

venous thromboembolism
atrial fibrillation
end stage renal disease
ejection fraction
pulmonary embolism
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
type diabetes
adipose tissue
insulin resistance
weight loss